APLIF - Appili Therapeutics expands late-stage COVID-19 trial into Mexico and Brazil

Appili Therapeutics (APLIF) announces that it has added several clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating Avigan/Reeqonus (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19.The company said that the expansion would allow for the timely completion of the trial, and added that it expects to post topline data from the study in Q3 2021.The primary goal of the study is to demonstrate a significant shortening of the time to sustained recovery for study patients receiving the experimental medicine compared to a placebo. Appili has also planned a late-stage trail designed to evaluate the combination for the prevention of COVID-19 when given to asymptomatic individuals who have had direct exposure (within 72 hours) to an infected person.The company expects to initiate enrollment for the study in the second half of 2021.

For further details see:

Appili Therapeutics expands late-stage COVID-19 trial into Mexico and Brazil